Shandong Boan Biotechnology Company., Limited. Class H (HK:6955) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Shandong Boan Biotechnology Co., Ltd. has announced the approval to commence clinical trials in China for BA1302, a novel antibody-drug conjugate targeting CD228 in advanced solid tumors. This marks the first CD228-targeted ADC to enter clinical trials in China, with BA1302 showing promise in preclinical studies due to its potent anti-tumor activity, favorable pharmacokinetics, and good safety profile. BA1302 stands as the only such ADC at the clinical stage worldwide, potentially offering a new effective treatment for various solid tumors.
For further insights into HK:6955 stock, check out TipRanks’ Stock Analysis page.